Even though IL-22-secreting CAR T cells showed higher in vivo persistence, the main reason for the improved antitumoral activity was that IL-22 upregulates MUC1 expression in cancer cells, allowing a more effective recognition by CAR T cells [161]. Here, IL22 is linked to cancer.